Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma

Clinical Trial ID NCT01815749

Rank	Title	Journal	Year	PubWeight™‹?›
1	Antibody-modified T cells: CARs take the front seat for hematologic malignancies.	Blood	2014	2.84
2	Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.	Int J Hematol	2013	1.64
3	Adoptive immunotherapy for cancer or viruses.	Annu Rev Immunol	2014	1.61
4	Trial Watch: Adoptive cell transfer for anticancer immunotherapy.	Oncoimmunology	2014	0.96
5	Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.	Blood	2016	0.89
6	Driving CAR-based T-cell therapy to success.	Curr Hematol Malig Rep	2014	0.89
7	Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches.	Leukemia	2014	0.86
8	Trial Watch: Adoptive cell transfer for oncological indications.	Oncoimmunology	2015	0.84
9	Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances.	Ther Adv Hematol	2015	0.82
10	Targeting CD8+ T-cell tolerance for cancer immunotherapy.	Immunotherapy	2014	0.81
11	Challenges and opportunities of allogeneic donor-derived CAR T cells.	Curr Opin Hematol	2015	0.79
12	Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy.	Immunotargets Ther	2015	0.75